You are here: Home » Companies » News
Business Standard

Bulk drug makers eye Japanese generic market

India has free trade agreement with Japan, which also aids in forming alliances with Japanese firms

Sohini Das  |  Mumbai/ Ahmedabad 

Japan has emerged as a focus market for Indian bulk drug makers. Active pharmaceutical ingredient (API) makers like Ahmedabad-based Dishman Pharmaceuticals, Hyderabad-based Suven Lifesciences and Chandigarh-based Ind-Swift Labs are all upbeat on the Japanese market.

Dishman Pharmaceuticals and Chemicals, which is supplying to eleven in Japan already and has seven APIs approved by the country's drug regulator, is eyeing a five-fold growth in revenue from Japan this fiscal (2012-13).

"We are going to touch around $10 million in revenues from Japan, which is up five to seven times from last year, when we had supplied APIs worth $1.2-2 million to Japan," claimed J R Vyas, chairman and managing director of Dishman.

He added that the company has a pipeline of eleven APIs waiting for approval from the Pharmaceuticals and Medical Devices Agency (PMDA), the drug regulator of Japan.

A few years back, Japan had decided to switch from expensive patented drugs to cheaper generic versions. Also, the expiry of patents of several block-buster drugs, threw up an opportunity for generic drug makers, and, in turn, for API makers who supply ingredients to formulation makers.

India also has a free trade agreement with Japan, which also aids in forming alliances with Japanese

The government is trying to promote use of generic drugs and has included this into the outline of the draft proposal for comprehensive tax and social security reform in February 2012.

Hyderabad-based Suven Lifesciences, which is supplying to generic drug makers in Japan, is also looking out to sign similar supply deals with at least three more this year.

A senior official of the company informed that Indian API makers, who already export to several countries, find it easy to meet regulatory requirements for supplying to Japan.

Chandigarh-based Ind-Swift Labs, has around six to seven approvals in place in Japan. The company is looking to tap the anti-diabetic, anti-cholesterol market in Japan, as generic drug makers are bullish on these segments.

The Pharmaceuticals Export Promotion Council of India (Pharmexcil) is taking a delegation to Japan during April 24-26 this year.

In a notification on its website, the export promotion council noted that India's export of bulk drugs to Japan had grown by around 50.3 per cent in 2011-12 over previous year to $87 million. This fiscal's figures are yet to be collated.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, March 31 2013. 20:28 IST